Labcorp Holdings LH Biopharma Laboratory Services — Revenue
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Labcorp Holdings in its filing.
Tagged under the XBRL concept us-gaap:Revenues.
The official record: Labcorp Holdings’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about Labcorp Holdings's biopharma laboratory services — revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Labcorp Holdings's biopharma laboratory services — revenue?
- Labcorp Holdings (LH) reported biopharma laboratory services — revenue of $780.6M in Q1 2026.
- How has Labcorp Holdings's biopharma laboratory services — revenue changed year-over-year?
- Labcorp Holdings's biopharma laboratory services — revenue increased by 8.2% year-over-year, from $721.3M to $780.6M.
- What is the long-term trend for Labcorp Holdings's biopharma laboratory services — revenue?
- Over 3 years (2022 to 2025), Labcorp Holdings's biopharma laboratory services — revenue has grown at a 4.7% compound annual growth rate (CAGR), from $2.7B to $3.1B.
- What does biopharma laboratory services — revenue mean?
- This represents the total gross income generated by the Biopharma Laboratory Services segment from providing laboratory and clinical trial support services to biopharmaceutical clients. It is the primary indicator of the segment's market demand and top-line performance.